Prometheus Anser IFX
Test Mnemonic
ANSIFX
CPT Codes
- 80230 - QTY (1)
- 82542 - QTY (1)
Includes
- Serum infliximab concentration
- Antibody to infliximab partial concentration
- Antibodies to infliximab (ATI) concentration
Performing Laboratory
Prometheus
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Serum | SST (Gold) | Refrigerated | Ship using cold pack |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Serum | No additive (Red) | Refrigerated | Ship using cold pack |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Adult patients | ||||
| 0.5 mL | Pediatric patients |
Stability
| Environmental Condition | Description |
|---|---|
| Refrigerated | 9 days |
| Ambient | 7 days |
| Frozen | Unacceptable |
Days Performed
Varies
Turnaround Time
4 - 5 days
Methodology
| Name | Description |
|---|---|
| High Performance Liquid Chromatography (HPLC) |
Clinical Info
Serum concentrations of infliximab (IFX) can vary among equally dosed patients, which can ultimately affect patient outcomes. Suboptimal levels of IFX have been linked to lower response rates in IBD patients. Additionally, some patients may develop immunogenicity to IFX by producing antibodies to infliximab (ATI). The presence of ATI has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of IFX and ATI levels in serum provides clinicians with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response. The Prometheus Anser IFX test is a next generation and more sensitive quantitative monitoring assay that allows healthcare providers to measure and monitor serum IFX and ATI levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.